keyword
MENU ▼
Read by QxMD icon Read
search

Cancer-related Fatigue

keyword
https://www.readbyqxmd.com/read/28822063/mind-body-therapies-in-cancer-what-is-the-latest-evidence
#1
REVIEW
Linda E Carlson, Erin Zelinski, Kirsti Toivonen, Michelle Flynn, Maryam Qureshi, Katherine-Ann Piedalue, Rachel Grant
PURPOSE OF REVIEW: Many people living with cancer use complementary therapies, and some of the most popular are mind-body therapies (MBTs), including relaxation and imagery, hypnosis, yoga, meditation, tai chi and qigong, and art therapies. The efficacy of these modalities was reviewed by assessing recent findings in the context of cancer care. RECENT FINDINGS: These therapies show efficacy in treating common cancer-related side effects, including nausea and vomiting, pain, fatigue, anxiety, depressive symptoms and improving overall quality of life...
August 18, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28822053/colorectal-cancer-patient-s-self-efficacy-for-managing-illness-related-problems-in-the-first-2%C3%A2-years-after-diagnosis-results-from-the-colorectal-well-being-crew-study
#2
Chloe Grimmett, Joanne Haviland, Jane Winter, Lynn Calman, Amy Din, Alison Richardson, Peter W F Smith, Claire Foster
PURPOSE: There is a growing emphasis on self-management of cancer aftercare. Little is known about patient's self-efficacy (confidence) to manage illness-related problems and how this changes over time. This paper describes the patterns of self-efficacy for managing illness-related problems amongst colorectal cancer patients in the 2 years following diagnosis. METHODS: In this prospective cohort study, questionnaires were administered at baseline (pre-surgery), 3, 9, 15 and 24 months to 872 colorectal cancer patients...
August 19, 2017: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/28821284/physical-exercise-following-esophageal-cancer-treatment-perfect-study-design-of-a-randomized-controlled-trial
#3
Jonna K van Vulpen, Peter D Siersema, Richard van Hillegersberg, Grard A P Nieuwenhuijzen, Ewout A Kouwenhoven, Richard P R Groenendijk, Donald L van der Peet, Eric J Hazebroek, Camiel Rosman, Carlo C G Schippers, Elles Steenhagen, Petra H M Peeters, Anne M May
BACKGROUND: Following esophagectomy, esophageal cancer patients experience a clinically relevant deterioration of health-related quality of life, both on the short- and long-term. With the currently growing number of esophageal cancer survivors, the burden of disease- and treatment-related complaints and symptoms becomes more relevant. This emphasizes the need for interventions aimed at improving quality of life. Beneficial effects of post-operative physical exercise have been reported in several cancer types, but so far comparable evidence in esophageal cancer patients is lacking...
August 18, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28819367/short-term-effectiveness-of-inpatient-cancer-rehabilitation-a-longitudinal-controlled-cohort-study
#4
Maria Ture, Felix Angst, André Aeschlimann, Christoph Renner, Ulrich Schnyder, Nic Zerkiebel, Josef Perseus, Jürgen Barth, Marius Bredell, Chantal Martin Soelch, Heinrich Walt, Josef Jenewein
Background: Inpatient rehabilitation for cancer patients has been demonstrated to improve patients' health related quality of life (HRQoL) effectively. The purpose of this study was to compare changes in general health and HRQoL of cancer patients who were referred to inpatient rehabilitation (IR) with those in two control groups who underwent outpatient management either with advice for inpatient rehabilitation (A(+)) or without (A(-)). Methods: In this naturalistic, longitudinal, controlled cohort study, changes in general health and HRQoL were assessed at either discharge of acute hospital or start of rehabilitation (baseline) and at the follow-up 3 weeks later or end of rehabilitation...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28817373/cabozantinib-as-salvage-therapy-for-patients-with-tyrosine-kinase-inhibitor-refractory-differentiated-thyroid-cancer-results-of-a-multicenter-phase-ii-international-thyroid-oncology-group-trial
#5
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah
Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). However, there are no approved second- or third-line therapies. MET is implicated in resistance to VEGFR inhibitors. Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR and is approved for medullary thyroid cancer. In a phase I study of cabozantinib, five of eight patients with DTC previously treated with a VEGFR-targeted therapy had an objective response to cabozantinib...
August 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28816636/the-distress-thermometer-predicts-subjective-but-not-objective-cognitive-complaints-six-months-after-treatment-initiation-in-cancer-patients-receiving-a-curative-cancer-treatment
#6
Michelle Lycke, Tessa Lefebvre, Lies Pottel, Hans Pottel, Lore Ketelaars, Karin Stellamans, Koen Van Eygen, Philippe Vergauwe, Patrick Werbrouck, Laurence Goethals, Patricia Schofield, Tom Boterberg, Philip R Debruyne
OBJECTIVES: Research has indicated that cancer-related cognitive impairments (CRCI) may be influenced by psychosocial factors such as distress, worry and fatigue. Therefore, we aimed to validate the distress thermometer (DT) as a screening tool to detect CRCI six months post treatment initiation in a group of general cancer patients. METHODS: Patients(18 years, n 125) with a histologically confirmed diagnosis of a solid cancer or haematological malignancy, scheduled for a curative treatment, were evaluated at baseline (T0) and six months post-treatment initiation (T1) for CRCI by a neuropsychological assessment including patient-reported outcome measures (PROMs)...
August 17, 2017: Journal of Psychosocial Oncology
https://www.readbyqxmd.com/read/28816142/vorinostat-and-concurrent-stereotactic-radiosurgery-for-non-small-cell-lung-cancer-brain-metastases-a-phase-1-dose-escalation-trial
#7
Clara Y H Choi, Heather A Wakelee, Joel W Neal, Mary C Pinder-Schenck, Hsiang-Hsuan Michael Yu, Steven D Chang, John R Adler, Leslie A Modlin, Griffith R Harsh, Scott G Soltys
PURPOSE: To determine the maximum tolerated dose (MTD) of vorinostat, a histone deacetylase inhibitor, given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLC) brain metastases. Secondary objectives were to determine toxicity, local failure, distant intracranial failure, and overall survival rates. MATERIALS AND METHODS: In this multicenter study, patients with 1 to 4 NSCLC brain metastases, each ≤2 cm, were enrolled in a phase 1, 3 + 3 dose escalation trial...
September 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28814476/phase-i-trial-of-the-androgen-receptor-modulator-cr1447-in-breast-cancer
#8
Martin Zweifel, Beat Thuerlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa
CR 1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in pre-clinical studies. The objective of this first-in man trial was to evaluate safety and to determine the dose of CR1447, administered as an ointment, for Phase II. Escalating doses (100, 200, 400 mg) of CR1447 were administered topically on a daily basis to patients with ER-positive/AR-positive/HER2-negative advanced breast cancer pretreated with several lines of therapy...
August 16, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28813164/pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer-results-from-the-phase-ib-keynote-028-study
#9
Patrick A Ott, Elena Elez, Sandrine Hiret, Dong-Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M Mehnert
Purpose The safety and efficacy of pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), were assessed in patients with programmed death ligand 1 (PD-L1)-expressing extensive-stage small-cell lung cancer (SCLC) in the multicohort, phase Ib open-label KEYNOTE-028 study ( ClinicalTrials.gov identifier: NCT02054806). Methods Patients with SCLC received pembrolizumab 10 mg/kg every 2 weeks for 24 months or until disease progression or intolerable toxicity occurred. PD-L1 expression was assessed by immunohistochemistry...
August 16, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28811271/-am-i-normal-the-wishes-of-patients-with-lymphoma-to-compare-their-patient-reported-outcomes-with-those-of-their-peers
#10
Simone Oerlemans, Lindy P Arts, Nicole J Horevoorts, Lonneke V van de Poll-Franse
BACKGROUND: Providing feedback to patients on their patient-reported outcomes (PROs) can help patients in monitoring their functioning and symptoms and may help empower them. OBJECTIVE: The objective of this study was to investigate whether patients with lymphoma wished to receive PRO feedback, including the option to compare their scores with those of their peers, and how this feedback was evaluated. METHODS: We invited 64 patients participating in a lymphoma cohort who were eligible for a follow-up questionnaire and gave them the option to receive PRO feedback...
August 15, 2017: Journal of Medical Internet Research
https://www.readbyqxmd.com/read/28805667/the-effect-of-a-standardized-ginger-extract-on-chemotherapy-induced-nausea-related-quality-of-life-in-patients-undergoing-moderately-or-highly-emetogenic-chemotherapy-a-double-blind-randomized-placebo-controlled-trial
#11
Wolfgang Marx, Alexandra L McCarthy, Karin Ried, Dan McKavanagh, Luis Vitetta, Avni Sali, Anna Lohning, Elisabeth Isenring
Ginger supplementation could be an effective adjuvant treatment for chemotherapy-induced nausea (CIN). The aim of this clinical trial was to address significant methodological limitations in previous trials. Patients (N = 51) were randomly allocated to receive either 1.2 g of standardised ginger extract or placebo per day, in addition to standard anti-emetic therapy, during the first three cycles of chemotherapy. The primary outcome was CIN-related quality of life (QoL) measured with the Functional Living Index- Emesis (FLIE) questionnaire...
August 12, 2017: Nutrients
https://www.readbyqxmd.com/read/28798986/a-phase-ii-multicentre-open-label-proof-of-concept-study-of-tasquinimod-in-hepatocellular-ovarian-renal-cell-and-gastric-cancers
#12
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, Nathalie Germann, Jean-Christophe Pouget, Ruth Plummer, Ignace Vergote, Fiona Thistlethwaite, Georg A Bjarnason, Robert Jones, Helen Mackay, Julien Edeline, Laetitia Fartoux, Hal Hirte, Amit Oza
BACKGROUND: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors. PATIENTS AND METHODS: This early stopping design, open-label, proof-of-concept clinical trial evaluated the clinical activity of tasquinimod in four independent cohorts of patients with advanced hepatocellular (n = 53), ovarian (n = 55), renal cell (n = 38), and gastric (n = 21) cancers...
August 10, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28797855/exploring-genetic-attributions-underlying-radiotherapy-induced-fatigue-in-prostate-cancer-patients
#13
Sepehr Hashemi, Juan Luis Fernandez Martinez, Leorey Saligan, Stephen Sonis
CONTEXT: Despite numerous proposed mechanisms, no definitive pathophysiology underlying Radiotherapy-Induced Fatigue (RIF) has been established. However, the dysregulation of a set of 35 genes was recently validated to predict development of fatigue in prostate cancer patients (PCP's) receiving radiotherapy. OBJECTIVES: To hypothesize novel pathways, and provide genetic targets for currently proposed pathways implicated in RIF development through analysis of the previously validated gene set...
August 7, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28792245/a-phase-2-study-of-5-fluorouracil-5-fu-ziv-aflibercept-and-radiation-for-the-preoperative-and-adjuvant-treatment-of-patients-with-stage-ii-iii-rectal-cancer
#14
Johanna C Bendell, Dana Thompson, Brian M Hemphill, David Wenk, Chris Earwood, Cassie M Lane, Andrew Kennedy
BACKGROUND: This phase II study combined aflibercept with preoperative chemoradiation for patients with stage II/III rectal cancer, followed by mFOLFOX6/aflibercept. METHODS: Patients received preoperative 5-FU (days 1-43), radiation (weeks 1-6), and aflibercept (days 1-15) each 28 day cycle for 6 weeks. Six weeks following the last aflibercept dose, patients underwent surgical resection. Four cycles of mFOLFOX6 plus aflibercept began 8 weeks after surgery. RESULTS: Common treatment-related toxicities included diarrhea, fatigue, and mucositis...
August 9, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28777395/health-related-quality-of-life-of-cancer-patients-with-peripherally-inserted-central-catheter-a-pilot-study
#15
Junren Kang, Wei Chen, Wenyan Sun, Ruibin Ge, Hailong Li, Enling Ma, Qingxia Su, Fang Cheng, Jinhua Hong, Yuanjuan Zhang, Cheng Lei, Xinchuan Wang, Aiyun Jin, Wanli Liu
INTRODUCTION: This pilot exploratory study aimed to compare the health-related quality of life (HRQOL) among patients diagnosed with different types of cancer receiving peripherally inserted central catheters (PICCs). METHODS: A multicenter cross-section study of cancer patients with PICCs was performed from February 1, 2013 to April 24, 2014. The primary objective of this study was to compare HRQOL in different cancer type patients with PICC. HRQOL was examined based on European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30)...
July 26, 2017: Journal of Vascular Access
https://www.readbyqxmd.com/read/28764748/a-phase-i-trial-of-ganetespib-in-combination-with-paclitaxel-and-trastuzumab-in-patients-with-human-epidermal-growth-factor-receptor-2-her2-positive-metastatic-breast-cancer
#16
Komal Jhaveri, Rui Wang, Eleonora Teplinsky, Sarat Chandarlapaty, David Solit, Karen Cadoo, James Speyer, Gabriella D'Andrea, Sylvia Adams, Sujata Patil, Sofia Haque, Tara O'Neill, Kent Friedman, Francisco J Esteva, Clifford Hudis, Shanu Modi
BACKGROUND: Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clinical activity. We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-positive metastatic breast cancer...
August 2, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28763368/veliparib-monotherapy-to-patients-with-brca-germ-line-mutation-and-platinum-resistant-or-partially-platinum-sensitive-relapse-of-epithelial-ovarian-cancer-a-phase-i-ii-study
#17
Karina Dahl Steffensen, Parvin Adimi, Anders Jakobsen
OBJECTIVE: A new treatment principle, which seems to radically change the treatment approach in ovarian cancer (OC), has developed over the past few years. Poly(ADP-ribose) polymerase inhibitors work by interfering with mechanisms important to DNA damage repair. Cancer cells that already have defects in the BRCA genes are particularly sensitive to treatment with poly(ADP-ribose) polymerase inhibitors. The main purpose of this study was to investigate the effect of veliparib in patients with known BRCA1/2 mutations and with a platinum-resistant or intermediate sensitive relapse of OC...
August 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28761731/health-related-quality-of-life-in-a-randomised-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-and-gemcitabine-alone-for-locally-advanced-or-metastatic-pancreatic-cancer-gest-study
#18
Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
OBJECTIVE: This study was performed to compare health-related quality of life (HRQOL) of gemcitabine plus S-1 (GS), S-1 alone and gemcitabine alone as first-line chemotherapy for locally advanced or metastatic pancreatic cancer in the GEST (Gemcitabine and TS-1 Trial) study and to assess the impacts of adverse events and tumour response on HRQOL. METHODS: Patients were randomly assigned to receive gemcitabine alone (1000 mg/m(2) weekly for 3 of 4 weeks), S-1 alone (80, 100 or 120 mg/day twice daily for 4 of 6 weeks) or GS (gemcitabine at 1000 mg/m(2) weekly plus S-1 at 60, 80 or 100 mg/day twice daily for 2 of 3 weeks)...
2017: ESMO Open
https://www.readbyqxmd.com/read/28760403/health-related-quality-of-life-for-immediate-versus-delayed-androgen-deprivation-therapy-in-patients-with-asymptomatic-non-curable-prostate-cancer-trog-03-06-and-vcog-pr-01-03-toad-a-randomised-multicentre-non-blinded-phase-3-trial
#19
Gillian M Duchesne, Henry H Woo, Madeleine King, Steven J Bowe, Martin R Stockler, Alice Ames, Catherine D'Este, Mark Frydenberg, Andrew Loblaw, Shawn Malone, Jeremy Millar, Keen Hun Tai, Sandra Turner
BACKGROUND: Androgen-deprivation therapy in patients with prostate cancer who have relapsed with rising prostate-specific antigen concentration only (PSA-only relapse), or with non-curable but asymptomatic disease at diagnosis, could adversely affect quality of life at a time when the disease itself does not. We aimed to compare the effect of immediate versus delayed androgen-deprivation therapy on health-related quality of life over 5 years in men enrolled in the TOAD (Timing of Androgen Deprivation) trial...
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28755959/an-open-label-single-arm-phase-ii-multicenter-study-of-the-safety-and-efficacy-of-cg0070-oncolytic-vector-regimen-in-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-cancer-interim-results
#20
Vignesh T Packiam, Donald L Lamm, Daniel A Barocas, Andrew Trainer, Benjamin Fand, Ronald L Davis, William Clark, Michael Kroeger, Igor Dumbadze, Karim Chamie, A Karim Kader, Dominic Curran, John Gutheil, Arthur Kuan, Alex W Yeung, Gary D Steinberg
OBJECTIVES: CG0070 is a replication-competent oncolytic adenovirus that targets bladder tumor cells through their defective retinoblastoma pathway. Prior reports of intravesical CG0070 have shown promising activity in patients with high-grade non-muscle invasive bladder cancer (NMIBC) who previously did not respond to bacillus Calmette-Guérin (BCG). However, limited accrual has hindered analysis of efficacy, particularly for pathologic subsets. We evaluated interim results of a phase II trial for intravesical CG0070 in patients with BCG-unresponsive NMIBC who refused cystectomy...
July 26, 2017: Urologic Oncology
keyword
keyword
39571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"